TSS
RNAC icon

Two Sigma Securities’s Cartesian Therapeutics RNAC Stock Holding History

Two Sigma Securities’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-435
Closed -$13.8K – 3497
2023
Q3 		$13.8K Sell
435
-481
-53% -$16.1K ﹤0.01% 2639
2023
Q2 		$30.8K Buy
916
+348
+61% +$12.5K ﹤0.01% 2456
2023
Q1 		$23.7K Buy
+568
New +$26.7K ﹤0.01% 2342
2022
Q3 		– Sell
-1,255
Closed -$49K – 3018
2022
Q2 		$49K Buy
1,255
+826
+193% +$24.5K ﹤0.01% 1848
2022
Q1 		$16K Buy
+429
New +$26.8K ﹤0.01% 2005

Other funds holding RNAC

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Securities's RNAC Position: Q4 2023 in Review

Two Sigma Securities sold out of Cartesian Therapeutics (RNAC) in Q4 2023, closing a stake of 435 shares — an estimated $13.8K sold.

Two Sigma Securities first reported a position in RNAC in Q1 2022 and held it in 5 quarters. The position peaked at $49K in Q2 2022. 80 funds tracked by Wall St. Rank hold RNAC as of Q4 2023.

  • Two Sigma Securities reported no remaining Cartesian Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Two Sigma Securities sold 435 Cartesian Therapeutics shares in Q4 2023, an estimated $13.8K.
  • Two Sigma Securities first reported a position in Cartesian Therapeutics in Q1 2022 and held it in 5 quarters.
  • Two Sigma Securities's Cartesian Therapeutics position peaked at $49K in Q2 2022.
  • 80 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2023.

Based on Two Sigma Securities's 13F filing for Q4 2023, filed 14 Feb 2024.